Royalty Reports; Payments. Within forty-five (45) calendar days after the end of any calendar quarter, Novartis shall provide Infinity with a report stating the sales in units and in value of the Licensed Product made by Novartis or its Affiliates in the Territory, on a country by country basis, together with the calculation of the royalties due to Infinity. Royalty payments shall be made by Novartis to the bank account indicated by Infinity within forty-five (45) calendar days after the receipt by Novartis of the relevant invoice issued by Infinity.
Royalty Reports; Payments. Commencing on the First Commercial Sale of a Product (other than a U.S. [***] Product) and for so long as Royalties are due under this Agreement, no later than [***] after the end of each Calendar Quarter, NVS will provide to HMI a written report (each, a “Royalty Report”), which Royalty Report will set forth: (a) the Net Sales (in local currency and United States Dollars) for such Calendar Quarter on a country-by-country and Product-by-Product basis; (b) the amount of any adjustments to such Royalties in accordance with Section 11.7.2 (Adjustments to Royalties); (c) the resulting total Royalties for the relevant Calendar Quarter in United States Dollars; and (d) if, applicable, Sales Milestone Payments owed to HMI listed by category. All Royalty Reports will be the Confidential Information of NVS. Upon receipt of such Royalty Report, HMI shall issue an invoice to [***]. Royalty payments for each Calendar Quarter will be due within [***] of receipt of such written invoice by HMI for the Calendar Quarter.
Royalty Reports; Payments. Within *** after the end of any Calendar Quarter, the Royalty Paying Party shall provide the Royalty Receiving Party with a report stating the sales in units and in value of the Licensed Product made by the Royalty Paying Party, its Affiliates, licensees and sublicensees, as applicable, in the Royalty Paying Party’s territory, on a country-by-country basis, together with the calculation of the royalties due to the Royalty Receiving Party, including the method used to calculate the royalties and the exchange rates used. Royalty payments shall be made by the Royalty Paying Party to the bank account indicated by the Royalty Receiving Party within *** after the end of the applicable Calendar Quarter; provided that the Royalty Receiving Party has issued the relevant invoice for royalty payment within *** after the Royalty Receiving Party’s receipt of the royalty report from the Royalty Paying Party. In the event the Royalty Receiving Party fails to issue an invoice within such *** period as described above, the Royalty Paying Party’s obligation to pay such amounts within *** after the end of the applicable Calendar Quarter shall be extended by the number of days that lapse between the date the Royalty Receiving Party should have invoiced the Royalty Paying Party and the date the Royalty Receiving Party actually invoices the Royalty Paying Party.
Royalty Reports; Payments. Within forty-five (45) days after the end of each Calendar Quarter during which there are Net Sales from the sale of a Licensed Product and/or a Diagnostic Licensed Product by Schering-Plough or an Affiliate giving rise to a payment obligation under Section 7.6 or 7.7, Schering-Plough shall submit to AVEO a report identifying its Net Sales for each Licensed Product or Diagnostic Licensed Product, in each case for each country for such Calendar Quarter, and the royalties and other amounts payable to AVEO pursuant to Sections 7.6 and 7.7. Concurrently with each such report, Schering-Plough shall pay to AVEO all amounts payable by it under Sections 7.6 and 7.7.
Royalty Reports; Payments. Following the First Commercial Sale of a Licensed Product, Novartis shall, within [**] following the end of each Contract Quarter, deliver to Alnylam a report stating the Net Sales in units and in value of the Licensed Product made by Novartis, its Affiliates and their respective licensees and sublicensees, on a country-by-country basis (consistent with Novartis's internal geographical organization thereof), together with the calculation of the royalties due to Alnylam. In the event that Alnylam agrees with Novartis's royalty calculation, Alnylam may submit an invoice to Novartis for such amounts. In the event that Alnylam does not agree with Novartis's royalty calculation, Alnylam may submit an invoice to Novartis for any undisputed amounts, which upon notice to Novartis of a dispute with respect to such royalty calculation, shall be without prejudice to Alnylam's rights and remedies with respect to any disputed amounts.
Royalty Reports; Payments. Within [**] days after the end of each calendar quarter, Amgen shall submit to Infinity a report, on the basis of each Royalty-Bearing Product (other than Royalty-Bearing Products for which Amgen has eliminated its royalty obligations pursuant to Section 4.5.2), providing in reasonable detail an accounting of all Net Sales made during such calendar quarter. Concurrently with each such report, Amgen shall pay to Infinity all royalties payable by it under Section 4.5, as follows: (a) Amgen shall make estimated royalty payments with each such report submitted with respect to any of the first three calendar quarters of any calendar year based on the lowest royalty tier set forth in Section 4.5.1(a) (taking into consideration Section 4.5.1(d), if applicable) into which Amgen’s aggregate annual Net Sales of each Royalty-Bearing Product for such year could fall based on year-to-date Net Sales of such Royalty-Bearing Product and (b) Amgen shall make royalty payments with each such report submitted with respect to the final calendar quarter of any calendar year based on the actual royalty tier set forth in Section 4.5.1(a) (taking into consideration Section 4.5.1(d), if applicable) into which Amgen’s aggregate annual Net Sales of each Royalty-Bearing Product for such year actually fell and include with such royalty payments any additional amounts necessary to make the total of all royalty amounts paid by Amgen with respect to all Net Sales of Royalty-Bearing Products for such calendar year correct based on the actual royalty tiers set forth in Section 4.5.1(a) (taking into consideration Section 4.5.1(d), if applicable) into which Amgen’s aggregate annual Net Sales of such Royalty-Bearing Products for such year actually fell.
Royalty Reports; Payments. Within [**] calendar days after the end of any [**] following the Agios Opt-Out Date, Celgene with respect to each Licensed Product shall provide Agios with a report stating the sales in units and in value of such Licensed Product made by Celgene, its Affiliates, licensees and sublicensees, as applicable, in the US Territory, on a country-by-country basis, together with the calculation of the royalties due to Agios, including the method used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this Section 9.5 shall be made by Celgene to the bank account indicated by Agios concurrently with the delivery of such report.
Royalty Reports; Payments. Within [***] days after the end of each Calendar Quarter following the Vividion Opt-Out Date, Celgene with respect to each Shared Product shall provide Vividion with a report stating the sales in units and in value of such Shared Product made by Celgene, its Affiliates, and Licensee Partners, as applicable, on a country-by- country basis, together with the calculation of the royalties due to Vividion, including the method used to calculate the royalties, the exchange rates used, and itemized deductions. Payments of all amounts payable under this Section 9.4 shall be made by Celgene to the bank account indicated by Vividion within [***] days from the end of each Calendar Quarter in which such payment accrues.
Royalty Reports; Payments. Celgene shall: (i) within [***] days following the end of each Calendar Quarter in which a royalty payment accrues, provide to Vividion a report for each country in the Territory in which sales of any Licensed Product occurred in the Calendar Quarter covered by such statement, specifying for such Calendar Quarter: the number of Licensed Products sold; the applicable royalty rate under this Agreement; the royalties payable in each country’s currency, including an accounting of deductions taken in the calculation of Annual Net Sales in accordance with Celgene’s Accounting Standards; the applicable exchange rate to convert from each country’s currency to U.S. Dollars under Section 9.7; and the royalty calculation and royalties payable in U.S. Dollars, and (ii) make the royalty payments owed to Vividion hereunder in accordance with such royalty report in arrears, within [***] days from the end of each Calendar Quarter in which such payment accrues.
Royalty Reports; Payments. The royalty described in Section 3.2 shall be calculated and paid on a calendar quarter basis during the Term. AMAG shall furnish to Access a written report, within forty five (45) days after the end of each calendar quarter (or portion thereof, if this Agreement terminates during a calendar quarter), showing (a) the Net Sales of all Devices sold by AMAG and its Affiliates and Sublicensees in the Territory during the reporting period; (b) the calculation of royalties thereon; (c) the then aggregate Net Sales for Devices for [***]; and (d) the calculation of royalties payable under this Agreement for such calendar quarter (or portion thereof). Royalties shown to have accrued by each royalty report shall be due and payable on the date such royalty report is due. All payments to be made by AMAG hereunder will be made in U.S. dollars by wire transfer to such bank account as Access may designate. AMAG shall keep complete and accurate records in sufficient detail to enable the royalties payable hereunder to be determined for a period of at least three (3) years from the date of each payment of royalties.
